Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 705-707

  Urbano, Maria ^a   Spiegel, David ^a   Rai, Aanmol ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DIAZEPAM; DONEPEZIL; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANXIETY DISORDER; AUDITORY HALLUCINATION; BIPOLAR DISORDER; CARDIOTOXICITY; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; FEMALE; GRIEF; HUMAN; LETTER; MAJOR DEPRESSION; MALE; MASTICATION; MOOD DISORDER; PAIN; PARKINSONISM; PRIORITY JOURNAL; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; MIDDLE AGED; TREATMENT WITHDRAWAL;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PIPERAZINES; QUINOLONES; RISPERIDONE; WITHHOLDING TREATMENT;

EID: 39649093451     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31815a5870     Document Type: Letter

References (17)

1. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003;53:1142-1145.
2. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:29-40.
3. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61: 21-26.
4. Salmoiraghi A, Odiyoor M. A case of Aripiprazole and extra-pyramidal side effects. J Psychopharmacol. 2006;20:592-593.
5. Komatsu S, Kirino E, Inoue Y, et al. Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy. Clin Neuropharmacol. 2005;28: 90-93.
6. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161: 414-425.
7. Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res. 2005; 77(2-3):129-139.
8. Zacher JL, Hatchett AD. Aripiprazole-induced movement disorder. Am J Psychiatry. 2006;163:160-161.
9. Sajbel TA, Cheney EM, DeQuardo JR. Aripiprazole-associated dyskinesia. Ann Pharmacother. 2005;39:200-201.
10. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr. 2006; 11:435-439.
11. Harrison TS, Perry CM. Aripiprazole - a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64: 1715-1736.
12. Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry. 1996;8:179-182.
13. Kafantaris V, Hirsch J, Saito E, et al. Treatment of withdrawal dyskinesia. J Am Acad Child Adolesc Psychiatry. 2005;44: 1102-1103.
14. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry. 2003;48:771-772.
15. Samaha A-N, Seeman P, Stewart J, et al. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986.
16. Miyamoto S, Duncan GE, Godd DC, et al. Therapeutics of schizophrenia. In: Davis KL, ed. Neuropsychopharmacology: the Fifth Generation of Progress. Nashville, TN: American College of Psychopharmacology; 2002:775-808.
17. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997;321:105-111.